Paper
Design, synthesis and structure–activity relationship of 4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-ones as potent p53-MDM2 inhibitors
Published Feb 1, 2017 · Weihong Zhou, Xu Xiguo, Jin Li
Chinese Chemical Letters
Q1 SJR score
12
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-ones are potent p53-MDM2 inhibitors with 4-fold selectivity for U2 OS and Saos-2 cells, offering a valuable scaffold for further development of p53-MDM
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
NVP-CGM097 is a potent and selective MDM2 inhibitor in phase 1 clinical trials for treating p53wt tumors, with excellent in vivo profile and potential for use in cancer therapy.
2015·159citations·Philipp Holzer et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
MDM2 inhibitors show potential as a promising cancer treatment, with seven compounds advanced into early-stage clinical trials for various human cancers.
2014·391citations·Yujun Zhao et al.·Journal of Medicinal Chemistry
Journal of Medicinal Chemistry
SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
SAR405838, an optimized inhibitor of MDM2-p53 interaction, effectively induces complete and durable tumor regression in mouse models of various cancers, with a single oral dose being sufficient for complete regression in the SJSA-1 model.
2014·243citations·Shaomeng Wang et al.·Cancer research
Cancer research
A novel drug discovery strategy: Mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways
The enantiomeric antitumor agent, targeting both p53 and NF-B pathways, shows potential for effective cancer therapy with synergistic effects in vitro and in vivo.
2014·10citations·Chunlin Zhuang et al.·Oncotarget
Oncotarget
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
RO8994, a potent and selective spiroindolinone MDM2 inhibitor, shows potential for cancer therapy by targeting the p53/MDM2 interaction.
2014·51citations·Zhuming Zhang et al.·Bioorganic & medicinal chemistry
Bioorganic & medicinal chemistry
Citations
Synthesis and Mechanism of p53‐MDM2 Inhibitors with Heterocyclic Structures: A Focused Review
Nutlins and other p53 small molecule inhibitors show potential for novel synthesis methods, potentially improving cancer treatment.
2023·0citations·Li‐Tao Ji et al.·ChemistrySelect
ChemistrySelect
Discovery of pyrazolopyrrolidinones as potent, broad-spectrum inhibitors of Leishmania infection
Pyazolopyrrolidinones show high potency against visceral leishmaniasis without harming host cells, making them a potential lead drug series for leishmaniasis treatment.
2023·3citations·John Kavouris et al.
Synthesis and Structure Elucidation of Novel Spirooxindole Linked to Ferrocene and Triazole Systems via [3 + 2] Cycloaddition Reaction
The novel heterocyclic hybrid spirooxindole synthesized by linking ferrocene and triazole systems via [3 + 2] cycloaddition reaction reveals a well-defined structure and covalent interactions.
2022·3citations·M. Altowyan et al.·Molecules
Molecules
Discovery of spirooxindole–ferrocene hybrids as novel MDM2 inhibitors
Spirooxindole-ferrocene hybrids, particularly compound 5d, show potential as novel MDM2 inhibitors, suppressing p53 degradation, promoting apoptosis, and promoting oxidative damage in cancer-targeted therapy.
2021·19citations·Jun-Shan Mu et al.·Chinese Chemical Letters
Chinese Chemical Letters
2,4-Diketo esters: Crucial intermediates for drug discovery.
2,4-diketo esters are crucial intermediates in drug discovery due to their versatile synthesis and potential clinical applications in various diseases.
2020·30citations·Nenad Joksimović et al.·Bioorganic chemistry
Bioorganic chemistry
Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors
Compound 5c, a novel S-DACO analogue, shows promising antiviral activity against HIV-1 replication, with potent activity comparable to AZT and EFV.
2020·9citations·Da-Xiong Li et al.·Chinese Chemical Letters
Chinese Chemical Letters
p53: An Attractive Therapeutic Target for Cancer.
P53-MDM2 inhibitors show promise as a promising cancer therapeutic strategy, with potential for druggability and optimization, and various clinical candidates categorized by scaffold type.
2020·17citations·K. R. Patel et al.·Current medicinal chemistry
Current medicinal chemistry
Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors
Sulfur-containing diarylbenzopyrimidines show potential as anti-HIV drugs due to their lower cytotoxicity, higher selectivity, and better cLog P values compared to lead compounds.
2020·26citations·Sheng Han et al.·Chinese Chemical Letters
Chinese Chemical Letters
Oxidative cross-dehydrogenative [2 + 3] annulation of α-amino ketones with α-keto esters: concise synthesis of clausenamide analogues.
This one-pot oxidative cross-dehydrogenative method provides high yields of densely functionalized pyrrolones, which can be reduced to multi-substituted pyrrolidinones, potentially aiding in Alzheimer's disease treatment.
2019·2citations·Vinod Bhajammanavar et al.·Organic & biomolecular chemistry
Organic & biomolecular chemistry